Mga Batayang Estadistika
| LEI | 549300FZUBUB7MHY8R17 |
| CIK | 1158895 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LeMaitre Vascular, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE |
|
| August 6, 2025 |
Second Amended and Restated By-laws of the Registrant Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF LEMAITRE VASCULAR, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the manner determined by the Board of Dir |
|
| August 6, 2025 |
Amendments to Second Amended and Restated By-laws of the Registrant Effective August 4, 2025 Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF LEMAITRE VASCULAR, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the Board of Directors manner determined |
|
| August 5, 2025 |
LeMaitre Q2 2025 Financial Results Exhibit 99.1 LeMaitre Q2 2025 Financial Results BURLINGTON, MA, August 5, 2025 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: ● Sales $64.2mm, +15% (+15% organic) ● Gross margin 70.0%, +110 bps ● Op. income $16.1mm, +12% ● Op. margin 25% |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2025 LeMaitre Vascular, Inc. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 63 Second Avenue, Burlington, MA 01803 (Address of Princ |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 1, 2025 |
LeMaitre Q1 2025 Financial Results Exhibit 99.1 LeMaitre Q1 2025 Financial Results BURLINGTON, MA, May 1, 2025 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: ● Sales $59.9mm, +12% (+13% organic) ● Gross margin 69.2%, +60 bps ● Op. income $12.6mm, +6% ● Op. margin 21% ● Ear |
|
| May 1, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS E |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| February 28, 2025 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 28, 2025 |
LeMaitre Vascular, Inc. Insider Trading Policy Exhibit 19.1 LEMAITRE VASCULAR, INC. INSIDER TRADING PROCEDURES SECTION I. PURPOSE It is generally illegal for any director, officer or employee of LeMaitre Vascular, Inc. or its subsidiaries (the “Company”), or any consultant to the Company, to trade in the securities of the Company while in the possession of material, nonpublic information about the Company. It is also generally illegal for any |
|
| February 28, 2025 |
LeMaitre Vascular, Inc. Compensation Recovery Program Exhibit 97.1 LEMAITRE VASCULAR, INC. COMPENSATION RECOVERY POLICY Adopted as of November 1, 2023 LeMaitre Vascular, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons |
|
| February 27, 2025 |
LeMaitre Q4 2024 Financial Results Exhibit 99.1 LeMaitre Q4 2024 Financial Results BURLINGTON, MA, February 27, 2025 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results ● Sales $55.7mm, +14% (+14% organic) vs. Q4 2023 ● Gross margin 69.3%, +121 bps ● Op. income $12 |
|
| February 27, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 13, 2025 |
LeMaitre Vascular, Inc. Offer Letter to Dorian LeBlanc Exhibit 10.1 January 24, 2025 Dorian LeBlanc 449 W Elm St Yarmouth, ME 04096 Dear Dorian: On behalf of LeMaitre Vascular, Inc., I am pleased to offer you the position of Chief Financial Officer, reporting to George LeMaitre, Chairman & Chief Executive Officer, with a start date of Monday, March 10, 2025. This offer of employment is contingent upon the Company’s satisfaction with our background ver |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 7, 2025 LeMaitre Vascular, Inc. |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| December 19, 2024 |
Exhibit 4.1 Execution Version LeMaitre Vascular, Inc. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of December 19, 2024 2.50% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 13 Article 2. The Notes 1 |
|
| December 17, 2024 |
LeMaitre Vascular Prices $150 Million Convertible Senior Notes EX-99.1 2 tm2430433d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 LeMaitre Vascular Prices $150 Million Convertible Senior Notes BOSTON, MA, December 16, 2024 - LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced the pricing of its offering of $150,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified |
|
| December 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| December 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| December 16, 2024 |
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering BOSTON, MA, December 16, 2024 - LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified instituti |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 31, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| October 31, 2024 |
LeMaitre Q3 2024 Financial Results Exhibit 99.1 LeMaitre Q3 2024 Financial Results BURLINGTON, MA, October 31, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results ● Sales $54.8mm, +16% (+16% organic) vs. Q3 2023 ● Gross margin 67.8%, +280 bps ● Op. income $13.1mm, +43% ● Op. margi |
|
| October 22, 2024 |
LMAT / LeMaitre Vascular, Inc. / Copeland Capital Management, LLC - SC 13G Passive Investment SC 13G 1 lemaitre-sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 26, 2024 LeMaitre Vascular, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0 |
|
| August 8, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0 |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| August 1, 2024 |
LeMaitre Q2 2024 Financial Results Exhibit 99.1 LeMaitre Q2 2024 Financial Results BURLINGTON, MA, August 1, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results ● Sales $55.8mm, +11% (+12% organic) vs. Q2 2023 ● Gross margin 68.9%, +490 bps ● Op. income $14.4mm, +52% ● Op. mar |
|
| August 1, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| June 3, 2024 |
LeMaitre Vascular, Inc. Fourth Amendment and Restated 2006 Stock Option and Incentive Plan Exhibit 10.1 LEMAITRE VASCULAR, INC. FOURTH AMENDED AND RESTATED 2006 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan (the “Plan”), which is the amendment and restatement of the Third Amended and Restated 2006 Stock Option and Incentive Plan. The |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2024 LeMaitre Vascular, Inc. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-33092 (State or other jurisdiction of incorporation or organization) (Commission File Number) 63 Second Avenue, Burlington, MA 01803 (Address of Principal Executive Offices) (Zip Code) Trent G. Kamk |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 2, 2024 |
LeMaitre Q1 2024 Financial Results Exhibit 99.1 LeMaitre Q1 2024 Financial Results BURLINGTON, MA, May 2, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results ● Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 ● Gross margin 68.6%, +300 bps ● Op. income $11.9mm, +51% ● Op. margin |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS E |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| February 29, 2024 |
LeMaitre Vascular, Inc. Compensation Recovery Program Exhibit 97.1 LEMAITRE VASCULAR, INC. COMPENSATION RECOVERY POLICY Adopted as of November 1, 2023 LeMaitre Vascular, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons |
|
| February 29, 2024 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| February 27, 2024 |
LeMaitre Q4 2023 Financial Results Exhibit 99.1 LeMaitre Q4 2023 Financial Results BURLINGTON, MA, February 27, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. |
|
| February 27, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 13, 2024 |
LMAT / LeMaitre Vascular, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01326-lemaitrevascularinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: LeMaitre Vascular Inc Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to de |
|
| February 12, 2024 |
LMAT / LeMaitre Vascular, Inc. / LeMaitre George W - SCHEDULE 13G/A Passive Investment SC 13G/A 1 lemg20240212sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 17)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 52555 |
|
| January 22, 2024 |
LMAT / LeMaitre Vascular, Inc. / Copeland Capital Management, LLC - SC 13G Passive Investment SC 13G 1 lemaitresc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 5, 2024 |
SC 13G/A 1 lmata710524.htm CONESTOGA CAPITAL ADVISORS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) |
|
| November 7, 2023 |
First Amendment of Lease dated October 18, 2023 between NWP Retail 18 LLC and the Registrant Exhibit 10.1 FIRST AMENDMENT OF LEASE THIS FIRST AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 18th day of October, 2023 (the “Effective Date”) by and between NWP RETAIL 18 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Massachusetts corporation (“Tenant”). BACKGROUND A. Landlord and Tenant originally entered into a lease date |
|
| November 7, 2023 |
Sixth Amendment of Lease dated October 18, 2023 between NWP Building 4 LLC and Registrant Exhibit 10.3 SIXTH AMENDMENT OF LEASE THIS SIXTH AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 18th day of September, 2023 (the “Effective Date”) by and between NWP BUILDING 4 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Massachusetts corporation (“Tenant”). BACKGROUND A. Landlord's predecessor-in-interest, the Trustees of N |
|
| November 7, 2023 |
Second Amendment of Lease dated October 18, 2023 between NWP Building 3 LLC and the Registrant Exhibit 10.2 SECOND AMENDMENT OF LEASE THIS SECOND AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 18th day of October, 2023 (the “Effective Date”) by and between NWP BUILDING 3 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Massachusetts corporation (“Tenant”). BACKGROUND A. Landlord's predecessor-in-interest, the trustee of N. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 7, 2023 |
Eighth Amendment of Lease dated October 18, 2023 between NWP Building 5 LLC and the Registrant Exhibit 10.4 EIGHTH AMENDMENT OF LEASE THIS EIGHTH AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 18th day of October, 2023 (the “Effective Date”) by and between NWP BUILDING 5 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Massachusetts corporation (“Tenant”). BACKGROUND A. Landlord's predecessor-in-interest, the Trustees of N |
|
| November 1, 2023 |
LeMaitre Q3 2023 Financial Results Exhibit 99.1 LeMaitre Q3 2023 Financial Results BURLINGTON, MA, November 1, 2023 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results ● Sales $47.4mm, +21% (+16% organic) vs. Q3 2022 ● Gross margin 65.0%, +80 bps ● Op. income $9.2mm, +49% ● Op. mar |
|
| November 1, 2023 |
Entry into a Material Definitive Agreement, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0 |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| August 1, 2023 |
LeMaitre Q2 2023 Financial Results Exhibit 99.1 LeMaitre Q2 2023 Financial Results BURLINGTON, MA, August 1, 2023 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results ● Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 ● Op. income $9.5mm, +63% (+8% adjusted) ● Op. margin 19% ● Net inc |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2023 LeMaitre Vascular, Inc. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-33092 (State or other jurisdiction of incorporation or organization) (Commission File Number) 63 Second Avenue, Burlington, MA 01803 (Address of Principal Executive Offices) (Zip Code) Trent G. Kamk |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 2, 2023 |
LeMaitre Q1 2023 Financial Results Exhibit 99.1 LeMaitre Q1 2023 Financial Results BURLINGTON, MA, May 2, 2023 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results ● Sales $47.1mm, +19% (+22% organic) vs. Q1 2022 ● Op. income $7.9mm, -1% ● Op. margin 17% ● Net income $6.0mm, flat ● |
|
| May 2, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS E |
|
| April 14, 2023 |
Draft 4.5.23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statem |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 1, 2023 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 23, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 23, 2023 |
LeMaitre Q4 2022 Financial Results Exhibit 99.1 LeMaitre Q4 2022 Financial Results BURLINGTON, MA, February 23, 2023 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results ● Sales $41.0mm, +4% (+8% organic) vs. Q4 2021 ● Op. income $7.0mm, -16% ● Op. margin 17% ● Net income $5. |
|
| February 9, 2023 |
LMAT / LeMaitre Vascular Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: LeMaitre Vascular Inc. Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 31, 2023 |
LMAT / LeMaitre Vascular Inc / LeMaitre George W - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 16)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2022 (Date of Ev |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 13, 2023 |
LMAT / LeMaitre Vascular Inc / Copeland Capital Management, LLC - SC 13G Passive Investment SC 13G 1 lemaitre13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 27, 2022 |
LeMaitre Q3 2022 Financial Results Exhibit 99.1 LeMaitre Q3 2022 Financial Results BURLINGTON, MA, October 27, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q3 2022 Financial Results ? Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021 ? Op. income $6.2mm, -32% ? Op. margin of 16% ? Net income of $ |
|
| October 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2022 LeMaitre Vascular, Inc. |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0 |
|
| July 28, 2022 |
LeMaitre Q2 2022 Financial Results Exhibit 99.1 LeMaitre Q2 2022 Financial Results BURLINGTON, MA, July 28, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q2 2022 Financial Results ? Sales of $42.1mm, +4% (+8% organic) vs. Q2 2021 ? Gross margin of 66.0% ? Op. income reported $5.8mm, -48% ? Op. i |
|
| July 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2022 LeMaitre Vascular, Inc. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-33092 (State or other jurisdiction of incorporation or organization) (Commission File Number) 63 Second Avenue, Burlington, MA 01803 (Address of Principal Executive Offices) (Zip Code) Trent G. Kamk |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| April 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| April 28, 2022 |
LeMaitre Q1 2022 Financial Results Exhibit 99.1 LeMaitre Q1 2022 Financial Results BURLINGTON, MA, April 28, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q1 2022 Financial Results ? Sales of $39.6mm, +10% (+13% organic) vs. Q1 2021 ? Op. income of $7.9mm, +0% ? Op. margin of 20% ? Net income of |
|
| April 14, 2022 |
DEF 14A 1 lmat20220412def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriat |
|
| February 28, 2022 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 28, 2022 |
Exhibit 10.36 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE LEMAITRE VASCULAR, INC. AMENDED AND RESTATED 2006 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE-BASED AWARD Name of Grantee: Target No. of Restricted Stock Units: Grant Date: LeMaitre Vascular, Inc. (the ?Company?) has selected you to be eligible to receive the target number of Restricted Stock Units identified above, subject to a |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| February 24, 2022 |
LeMaitre Q4 2021 Financial Results Exhibit 99.1 LeMaitre Q4 2021 Financial Results BURLINGTON, MA, February 24, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance. Q4 2021 Financial Results ? Sales of $39.5mm, +5% (+6% organic) vs. Q4 2020 ? Op. income of $8.3mm, -13% ? Op. margin of 21% ? Net |
|
| February 24, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 11, 2022 |
LMAT / LeMaitre Vascular Inc / LeMaitre George W - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2 (Amendment No. 15)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2021 (Date of Ev |
|
| February 10, 2022 |
LMAT / LeMaitre Vascular Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01295-lemaitrevascularinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: LeMaitre Vascular Inc. Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to d |
|
| January 26, 2022 |
LMAT / LeMaitre Vascular Inc / Copeland Capital Management, LLC - SC 13G Passive Investment SC 13G 1 lemaitre13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 2, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2021 LeMaitre Vascular, Inc. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 28, 2021 |
LeMaitre Q3 2021 Financial Results Exhibit 99.1 LeMaitre Q3 2021 Financial Results BURLINGTON, MA, October 28, 2021 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance. Q3 2021 Financial Results ? Sales of $38.4mm, +5% (+5% organic) vs. Q3 2020 ? Gross margin of 64.8%, +250 basis points ? Op. income of $9.1 |
|
| October 28, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| September 1, 2021 |
Exhibit 2.1 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This Amendment No.1 (the ?Amendment?) dated August 28, 2021 by and among LeMaitre Vascular, Inc., a Delaware corporation with an address at 63 Second Ave., Burlington, Massachusetts 01803 (the ?Purchaser?), Anteris Technologies Ltd, an Australian limited liability company with an address at Toowong Tower, Level 3, 9 Sherwood Rd, Toowong QLD 4 |
|
| September 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2021 LeMaitre Vascular, Inc. |
|
| August 5, 2021 |
EXHIBIT 10.3 LeMaitre Vascular, Inc. Director Compensation Policy Employee Directors Employee directors do not receive cash compensation for their service as members of the Board of Directors. Non-Employee Directors Non-employee directors receive an annual retainer for Board membership of $26,000. The chairman of our Audit Committee receives an annual retainer of $20,000, the chairman of our Compe |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33092 04-2825458 (State or other jurisdiction of incorporation) (Commission |
|
| July 29, 2021 |
LeMaitre Q2 2021 Financial Results Exhibit 99.1 LeMaitre Q2 2021 Financial Results BURLINGTON, MA, July 29, 2021 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2021 results, announced an $0.11/share quarterly dividend and provided guidance. Q2 2021 Financial Results ? Sales of $40.7mm, +64% (+35% organic) vs. Q2 2020 ? Op. income of $11.1mm, +128% ? Op. margin of 27% ? Net income |
|
| July 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS |
|
| July 16, 2021 |
Exhibit 1.1 1,000,000 Shares LeMaitre Vascular, Inc. UNDERWRITING AGREEMENT July 13, 2021 JEFFERIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED One Financial Plaza 501 North Broadway St. Louis, Missouri 63102 Ladies and Gentlemen: Introductory. |
|
| July 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33092 04-2825458 (State or other jurisdiction of incorporation) (Commission F |
|
| July 15, 2021 |
1,000,000 Shares LeMaitre Vascular, Inc. 424B5 1 lmat20210714424b5.htm FORM 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238541 PROSPECTUS SUPPLEMENT (to Prospectus dated May 20, 2020) 1,000,000 Shares LeMaitre Vascular, Inc. Common Stock We are offering 1,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “LMAT.” On July 13, 2021, the last reported |
|
| July 13, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238541 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus a |
|
| July 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 13, 2021 LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33092 04-2825458 (State or other jurisdiction of incorporation) (Commission F |
|
| July 13, 2021 |
LeMaitre Vascular Announces Proposed Public Offering of Common Stock Exhibit 99.2 LeMaitre Vascular Announces Proposed Public Offering of Common Stock BURLINGTON, Mass., July 13, 2021 ? LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by LeMaitre. In |
|
| July 13, 2021 |
LeMaitre Provides Q2 2021 Update Exhibit 99.1 LeMaitre Provides Q2 2021 Update BURLINGTON, Mass., July 13, 2021 ? LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021. Q2 2021 Preliminary Results ? Net Sales of $40.7mm, +64% reported, +35% organic vs. Q2 2020 ? Gross Margin of 65.5% to 66.1%, -2.7% |
|
| July 9, 2021 |
Eighth Amended and Restated Equity Award Grant Policy Exhibit 10.1 LEMAITRE VASCULAR, INC. EIGHTH AMENDED AND RESTATED EQUITY AWARD GRANT POLICY I. General Scope This Equity Award Grant Policy (this ?Policy?) establishes the process for LeMaitre Vascular, Inc. (the ?Company?) to follow when it grants shares of restricted or unrestricted stock, long term incentive awards, stock options, performance stock, or other equity-based awards (collectively, ?E |
|
| July 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 3, 2021 LeMaitre Vascular, Inc. |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2021 LeMaitre Vascular, Inc. |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 63 Second Avenue, Burlington, MA 01803 (Address of Principa |
|
| May 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| April 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| April 29, 2021 |
LeMaitre Q1 2021 Financial Results Exhibit 99.1 LeMaitre Q1 2021 Financial Results BURLINGTON, MA, April 29, 2021 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2021 results and announced an $0.11/share quarterly dividend. Q1 2021 Results ? Sales of $35.9mm, +17% (-5% organic) vs. Q1 2020 ? Op. income of $7.9mm, +83% ? Op. margin of 22% ? Net income of $5.9mm, +87% ? Earnings of $ |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 12, 2021 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 25, 2021 |
LeMaitre Q4 2020 Financial Results Exhibit 99.1 LeMaitre Q4 2020 Financial Results BURLINGTON, MA, February 25, 2021 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share quarterly dividend. Q4 2020 Results ? Sales of $37.5mm, +24% (+3% organic) vs. Q4 2019 ? Op. income of $9.5mm, +94% ? Op. margin of 25% ? Net income of $7.0mm, +52% ? Earnings o |
|
| February 25, 2021 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 14)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2020 (Date of Ev |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: LeMaitre Vascular Inc. Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 29, 2020 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| October 29, 2020 |
LeMaitre Vascular Announces Q3 2020 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q3 2020 Financial Results BURLINGTON, MA, October 29, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2020 results and announced a $0.095/share quarterly dividend. Q3 2020 Results ● Sales of $36.4mm, +25% (-3% organic) vs. Q3 2019 ● Op. income of $10.0mm, +70% ● Op. margin of 28% ● Net i |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0 |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2020 LeMaitre Vascular, Inc. |
|
| July 23, 2020 |
LeMaitre Vascular Announces Q2 2020 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q2 2020 Financial Results BURLINGTON, MA, July 23, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2020 results and announced a $0.095/share quarterly dividend. Q2 2020 Results ● Sales of $24.9mm, -16% (-24% organic) vs. Q2 2019 ● Op. income of $4.9mm, -18% ● Adjusted op. income of $6.1m |
|
| July 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS |
|
| June 24, 2020 |
LeMaitre Vascular Acquires Artegraft Exhibit 99.1 LeMaitre Vascular Acquires Artegraft BURLINGTON, Mass., June 22, 2020 - LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, including $72.5 million in cash paid at closing ($65.0 million to Artegraft plus $7.5 in escrow to be released December 31, 2021) as well as potential earnout payments of $17.5 millio |
|
| June 24, 2020 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT dated as of June 22, 2020 Among LEMAITRE VASCULAR, INC., as a Grantor, and KEYBANK NATIONAL ASSOCIATION, as the Administrative Agent, for the benefit of THE SECURED CREDITORS TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND TERMS 1 Section 1.01 Defined Terms 1 Section 1.02 Additional Defined Terms 1 Section 1.03 Terms Generally 7 ARTICLE II. SECURITY INT |
|
| June 24, 2020 |
Asset Purchase Agreement, dated June 22, 2020, by and between the Company and Artegraft, Inc. Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT Asset Purchase Agreement (this “Agreement”), dated June 22, 2020 by and between Lemaitre Vascular, Inc., a Delaware corporation with an address at 63 Second Ave |
|
| June 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS |
|
| June 24, 2020 |
Exhibit 10.1 CREDIT AGREEMENT dated as of June 22, 2020 among LEMAITRE VASCULAR, INC., as Borrower, THE LENDING INSTITUTIONS NAMED HEREIN, as Lenders, and KEYBANK NATIONAL ASSOCIATION, as an LC Issuer, Swing Line Lender and as the Administrative Agent, KeyBanc Capital Markets Inc. and SUNTRUST ROBINSON HUMPHREY, INC., each as a Joint Lead Arranger and a Joint Bookrunner $65,000,000 Senior Secured |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 63 Second Avenue, Burlington, MA 01803 (Address of Principal |
|
| May 28, 2020 |
May 28, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook Re: LeMaitre Vascular, Inc. (the “Company”) Registration Statement on Form S-3 Filed: May 20, 2020 File No. 333-238541 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests t |
|
| May 20, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Lemaitre Vascular, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Lemaitre Vascular, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Lemaitre Vascular, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and ex |
|
| May 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| May 20, 2020 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.3 Lemaitre Vascular, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sec |
|
| May 20, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 Lemaitre Vascular, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Lemaitre Vascular, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Lemaitre Vascular, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing un |
|
| May 20, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 LEMAITRE VASCULAR, INC. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Lemaitre Vascular, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Lemaitre Vascular, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and ex |
|
| May 20, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on May 20, 2020 Registration No. |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| April 30, 2020 |
LeMaitre Vascular Announces Q1 2020 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q1 2020 Financial Results BURLINGTON, MA, April 30, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2020 results and announced a $0.095/share quarterly dividend. Q1 2020 Results ● Record sales of $30.6mm, +7% (-1% organic) vs. Q1 2019 ● Operating income of $4.4mm, -2% ● Net income of $3. |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2020 LeMaitre Vascular, Inc. |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 13, 2020 LeMaitre Vascular, Inc. |
|
| April 14, 2020 |
Exhibit 99.1 LeMaitre Vascular Withdraws Prior Annual Guidance for 2020 And Announces Preliminary Q1 2020 Financial Results BURLINGTON, MA, April 13, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q1 2020 preliminary, unaudited results and withdrew prior annual guidance for 2020 due to the potential impact of COVID-19. Q1 2020 P |
|
| April 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IR |
|
| March 12, 2020 |
EXHIBIT 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of LeMaitre Vascular, Inc., or the Company, that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and is based on the provisions of our amended and restated cert |
|
| March 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 12, 2020 |
EXHIBIT 10.30 CERTAIN IDENTIFIED INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (“Agreement”) is effective October 11, 2019 (the “Effective Date”), by and among Admedus Ltd, a public limited company organized under the law |
|
| March 12, 2020 |
EXHIBIT 2.3 CERTAIN IDENTIFIED INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (this “Agreement”), dated October 11, 2019, by and among LeMaitre Vascular, Inc., a Delaware corporation with an address at 63 Second A |
|
| March 12, 2020 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 13, 2020 |
LMAT / LeMaitre Vascular, Inc. / LeMaitre George W - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 13)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2019 (Date of Ev |
|
| February 12, 2020 |
LMAT / LeMaitre Vascular, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 12, 2020 |
LMAT / LeMaitre Vascular, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: LeMaitre Vascular Inc Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 6, 2020 |
LeMaitre Vascular Announces Q4 2019 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q4 2019 Financial Results BURLINGTON, MA, February 6, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2019 results, provided guidance, and announced a $0.095/share dividend. Q4 2019 Results ● Record sales of $30.2mm, +6% (flat organic) vs. Q4 2018 ● Operating income of $4.9mm, -31% (-12% |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| January 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 3, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 26, 2019 LeMaitre Vascular, Inc. |
|
| December 3, 2019 |
Lease dated November 26, 2019 between NWP Retail 18 LLC and the Registrant. EXHIBIT 10.1 northwest park OFFICE lease by and between nwp retail 18 llc (AS LANDLORD) and LEMAITRE VASCULAR, INC. (AS TENANT) FOR PREMISES AT 32-34 THIRD AVENUE burlington, massachusetts NORTHWEST PARK OFFICE L E A S E ARTICLE 1 Reference Data 1.1 Subject Referred To. Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject |
|
| November 14, 2019 |
Exhibit 99.1 ADMEDUS LTD Carve-Out of the ADAPT® business segment “ADAPT® CARVE-OUT” FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018 CONTENTS ADAPT® Carve-Out Statement of Profit or loss 3 ADAPT® Carve-Out Statement of Other Comprehensive Income 4 ADAPT® Carve-Out Statement of Financial Position 5 ADAPT® Carve-Out Statement of Changes in Equity 6 ADAPT® Carve-Out Statement of Cash Flows 7 |
|
| November 14, 2019 |
Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On October 11, 2019, LeMaitre Vascular, Inc. (“LeMaitre” or “we”) acquired certain assets and a license related to the biologic cardiac and vascular patch business (the “ADAPT Carve-Out Business”) of Admedus Ltd and its subsidiaries (“Admedus”). The following unaudited pro forma condensed combined statements of operations ha |
|
| November 14, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 11, 2019 LeMaitre Vascular, Inc. |
|
| November 8, 2019 |
LMAT / LeMaitre Vascular, Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 1, 2019 |
Fifth Amendment of Lease dated October 29, 2019 between NWP BUILDING 4 LLC and the Registrant Exhibit 10.2 FIFTH amendment of lease THIS FIFTHAMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 29th day of October, 2019 (the “Effective Date”) by and between NWP BUILDING 4 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Delaware corporation (“Tenant”). Background A. Landlord's predecessor-in-interest, the Trustees of Northwest |
|
| November 1, 2019 |
Seventh Amendment of Lease dated October 29, 2019 between NWP BUILDING 5 LLC and the Registrant Exhibit 10.3 Seventh amendment of lease THIS SEVENTH AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 29th day of October, 2019 (the “Effective Date”) by and between NWP BUILDING 5 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Delaware corporation (“Tenant”). Background A. Landlord's predecessor-in-interest, the Trustees of Nort |
|
| November 1, 2019 |
First Amendment of Lease dated October 29, 2019 between NWP BUILDING 3 LLC and the Registrant Exhibit 10.1 First amendment of lease THIS FIRST AMENDMENT OF LEASE (this “Amendment”) is made and entered into as of this 29th day of October, 2019 (the “Effective Date”) by and between NWP BUILDING 3 LLC, a Massachusetts limited liability company (“Landlord”) and LEMAITRE VASCULAR, INC., a Delaware corporation (“Tenant”). Background A. Landlord and Tenant entered into an office lease dated Decem |
|
| November 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2019 LeMaitre Vascular, Inc. |
|
| October 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of ( |
|
| October 23, 2019 |
LeMaitre Vascular Announces Q3 2019 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q3 2019 Financial Results BURLINGTON, MA, October 23, 2019 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2019 results, provided guidance, and announced an $0.085/share dividend. Q3 2019 Results ● Sales of $29.1mm, +20% (+13% organic) vs. Q3 2018 ● Operating income of $5.9mm, +28% ● Net inco |
|
| October 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 11, 2019 LeMaitre Vascular, Inc. |
|
| October 17, 2019 |
LeMaitre Vascular Acquires Biologic Patch Business from Admedus EXHIBIT 99.1 LeMaitre Vascular Acquires Biologic Patch Business from Admedus BURLINGTON, Mass., Oct. 13, 2019 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced that it has acquired the biologic patch business of Admedus Ltd (ASX: AHZ) for $15.5 million, of which $14.2 million was paid at closing and $1.3 million is due in two post-closing installments, as well as potential earnout payments of $7 |
|
| August 6, 2019 |
LMAT / LeMaitre Vascular, Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0 |
|
| July 25, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2019 LeMaitre Vascular, Inc. |
|
| July 24, 2019 |
LeMaitre Vascular Announces Q2 2019 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q2 2019 Financial Results BURLINGTON, MA, July 24, 2019 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2019 results, provided guidance, and announced a $0.085/share dividend. Q2 2019 Results ● Record sales of $29.5mm, +9% (+5% organic) vs. Q2 2018 ● Operating income of $5.9mm vs. $11.5mm, -4 |
|
| July 24, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS |
|
| June 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2019 LeMaitre Vascular, Inc. |
|
| May 31, 2019 |
LMAT / LeMaitre Vascular, Inc. SD - - FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 63 Second Avenue, Burlington, MA 01803 (Address of Principal |
|
| May 6, 2019 |
LMAT / LeMaitre Vascular, Inc. 10-Q Quarterly Report FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of (IRS E |
|
| May 1, 2019 |
LeMaitre Vascular Announces Q1 2019 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q1 2019 Financial Results BURLINGTON, MA, May 1, 2019 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2019 results, provided guidance, and announced a $0.085/share dividend. Q1 2019 Results ● Record sales of $28.5mm, +10% (+7% organic) vs. Q1 2018 ● Operating income of $4.4mm vs. $4.9mm, -9% |
|
| April 17, 2019 |
LMAT / LeMaitre Vascular, Inc. FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 11, 2019 |
LMAT / LeMaitre Vascular, Inc. FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 11, 2019 |
EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vascutech Ac |
|
| February 19, 2019 |
LeMaitre Vascular Announces Q4 2018 Financial Results Exhibit 99.1 LeMaitre Vascular Announces Q4 2018 Financial Results BURLINGTON, MA, February 19, 2019 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2018 results, provided guidance, announced a 21% dividend increase to $0.085/share and announced a share repurchase program. Q4 2018 Results ● Record sales of $28.4mm, +9% (+6% organic) |
|
| February 19, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2019 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| February 13, 2019 |
LMAT / LeMaitre Vascular, Inc. / LeMaitre George W - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 12)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2018 (Date of Ev |
|
| February 11, 2019 |
LMAT / LeMaitre Vascular, Inc. / VANGUARD GROUP INC Passive Investment lemaitrevascularinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: LeMaitre Vascular Inc Title of Class of Securities: Common Stock CUSIP Number: 525558201 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriat |
|
| February 8, 2019 |
LMAT / LeMaitre Vascular, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| November 2, 2018 |
EX-2.1 EXHIBIT 2.1 ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (this “Agreement”), dated September 20, 2018, by and among LeMaitre Vascular, Inc., a Delaware corporation with an address at 63 Second Ave., Burlington, Massachusetts 01803 (the “Purchaser”) and Applied Medical Resources Corporation, a California corporation, with an address at 22872 Avenida Empresa, Rancho Santa Margarita, Cali |
|
| November 2, 2018 |
LMAT / LeMaitre Vascular, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 4, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction o |
|
| October 4, 2018 |
LeMaitre Vascular Announces Preliminary Q3 2018 Results EX-99.1 Exhibit 99.1 LeMaitre Vascular Announces Preliminary Q3 2018 Results BURLINGTON, MA, October 4, 2018 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q3 2018 preliminary unaudited results, provided Q4 2018 and updated full year 2018 guidance, and announced a $0.07/share dividend. Q3 2018 Preliminary Results • Sales of $24.2mm v |
|
| September 26, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdictio |
|
| September 26, 2018 |
LeMaitre Vascular Acquires Clot Management Business from Applied Medical EX-99.1 Exhibit 99.1 LeMaitre Vascular Acquires Clot Management Business from Applied Medical BURLINGTON, Mass., September 26, 2018 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it has acquired the vascular clot management business of Applied Medical Resources Corporation for $14.2 million, of which $11.0 million was paid at closing and $3.2 million will be paid in |
|
| August 6, 2018 |
LMAT / LeMaitre Vascular, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 26, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| July 26, 2018 |
LeMaitre Q2 2018 Record Sales $27.0mm (+5%), Record EPS $0.43 (+86%) EX-99.1 Exhibit 99.1 LeMaitre Q2 2018 Record Sales $27.0mm (+5%), Record EPS $0.43 (+86%) BURLINGTON, MA, July 26, 2018 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2018 results, provided guidance and announced a $0.07/share dividend. Q2 2018 Results • Record sales of $27.0mm, +5% vs. Q2 2017 • Record operating income of $11.5mm |
|
| June 8, 2018 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2018 LeMaitre Vascular, Inc. |
|
| May 31, 2018 |
LMAT / LeMaitre Vascular, Inc. SD SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 63 Second Avenue, Burlington, MA 01803 (Address of Princi |
|
| May 4, 2018 |
LMAT / LeMaitre Vascular, Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2018 |
EX-10.1 Exhibit 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (“Agreement”) is entered into as of April 5, 2018, by and between LeMaitre Vascular, Inc., a Delaware corporation with its principal place of business at 63 Second Avenue, Burlington, Massachusetts 01803 (“Seller”), and Specialty Surgical Instrumentation, Inc., a Tennessee corporation with its principal place of business a |
|
| April 25, 2018 |
LeMaitre Q1 2018 Sales $26.0mm (+8%), EPS $0.19 (+17%) EX-99.1 Exhibit 99.1 LeMaitre Q1 2018 Sales $26.0mm (+8%), EPS $0.19 (+17%) BURLINGTON, MA, April 25, 2018 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2018 results, provided guidance, and announced a $0.07/share dividend. Q1 2018 Results • Sales of $26.0mm, +8% vs. Q1 2017 • Operating income of $4.9mm vs. $4.2mm, +16% • Net inco |
|
| April 25, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| April 20, 2018 |
LMAT / LeMaitre Vascular, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| April 5, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction of |
|
| April 5, 2018 |
LeMaitre Vascular Divests General Surgery Product Lines EX-99.1 EXHIBIT 99.1 LeMaitre Vascular Divests General Surgery Product Lines BURLINGTON, Mass., April 5, 2018 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it has divested its general surgery product lines to Symmetry Surgical, Inc. for $7.4 million. Included in the divestiture were the Reddick Cholangiogram Catheter and Reddick Saye-Screw, both used during laparos |
|
| March 9, 2018 |
LMAT / LeMaitre Vascular, Inc. FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2018 |
EX-10.25 EXHIBIT 10.25 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE LEMAITRE VASCULAR, INC. 2006 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: LeMaitre Vascular, Inc. (the “Company”) has selected you to receive an award of the Restricted Stock Units identified above, subject to the terms set forth on Appendix A hereto, the provisions of the LeMaitre |
|
| March 9, 2018 |
EX-10.27 EXHIBIT 10.27 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER LEMAITRE VASCULAR, INC. 2006 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: Pursuant to the LeMaitre Vascular, Inc. 2006 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), L |
|
| March 9, 2018 |
EX-10.28 EXHIBIT 10.28 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER LEMAITRE VASCULAR, INC. 2006 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: [No more than 10 years] Pursuant to the LeMaitre Vascular, Inc. 2006 Stock Option and Incentive Plan, as amended through t |
|
| March 9, 2018 |
EX-10.26 EXHIBIT 10.26 INCENTIVE STOCK OPTION AGREEMENT UNDER LEMAITRE VASCULAR, INC. 2006 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [up to 10 years (5 if a 10% owner)] Pursuant to the LeMaitre Vascular, Inc. 2006 Stock Option and Incentive Plan as amended |
|
| March 9, 2018 |
EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of our subsidiaries: Name State or Other Jurisdiction of Incorporation Name Under Which Does Business LeMaitre Vascular GmbH Germany Same LeMaitre Vascular GK Japan Same LeMaitre Acquisition LLC Delaware Same LeMaitre Vascular SAS France Same LeMaitre Vascular Spain, S.L. Spain Same LeMaitre Vascular S.r.l. Italy Same Vasc |
|
| February 21, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d530852d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2018 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (S |
|
| February 21, 2018 |
LeMaitre Q4 2017 Record Sales $26.2mm (+12%), Record Op. Income $6.3mm (+62%) EX-99.1 Exhibit 99.1 LeMaitre Q4 2017 Record Sales $26.2mm (+12%), Record Op. Income $6.3mm (+62%) BURLINGTON, MA, February 21, 2018 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2017 results, provided guidance, and announced a 27% dividend increase to $0.07/share. Q4 2017 Results ? Record sales of $26.2mm, +12% vs. Q4 2016 ? Reco |
|
| February 14, 2018 |
LMAT / LeMaitre Vascular, Inc. / LeMaitre George W - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 11)* LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2017 (D |
|
| February 9, 2018 |
LMAT / LeMaitre Vascular, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LEMAITRE VASCULAR INC (Name of Issuer) Common Stock (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 8, 2018 |
LMAT / LeMaitre Vascular, Inc. FORM 10-K/A (Annual Report) Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| January 16, 2018 |
LMAT / LeMaitre Vascular, Inc. 10-Q/A (Quarterly Report) 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission F |
|
| January 16, 2018 |
LMAT / LeMaitre Vascular, Inc. FORM 10-Q/A (Quarterly Report) Form 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission F |
|
| January 16, 2018 |
LMAT / LeMaitre Vascular, Inc. 10-Q/A (Quarterly Report) 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| January 16, 2018 |
LMAT / LeMaitre Vascular, Inc. FORM 10-K/A (Annual Report) Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| January 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LeMaitre Vascular, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 525558201 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| December 18, 2017 |
LMAT / LeMaitre Vascular, Inc. CORRESP CORRESP 1 filename1.htm December 18, 2017 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Kevin J. Kuhar Re: LeMaitre Vascular, Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 9, 2017 Form 10-Q for the Quarterly Period Ended September 30, 2017 Filed November 3, 2017 File No. 001-33092 Ladies and Gentlemen: On behalf of Le |
|
| November 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 26, 2017 |
LeMaitre Q3 2017 Sales $24.8mm (+7%), Record EPS $0.25 (+49%) EX-99.1 Exhibit 99.1 LeMaitre Q3 2017 Sales $24.8mm (+7%), Record EPS $0.25 (+49%) BURLINGTON, MA, October 26, 2017 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2017 results, provided guidance, and announced a $0.055/share dividend. Q3 2017 Results ? Sales of $24.8mm, +7% vs. Q3 2016 ? Operating income of $5.1mm, -5% ? Record net |
|
| October 26, 2017 |
LeMaitre Vascular 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2017 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction |
|
| August 3, 2017 |
Separation Agreement dated June 7, 2017 between Peter R. Gebauer and LeMaitre Vascular GmbH EX-10.1 EXHIBIT 10.1 Aufhebungsvereinbarung Separation Agreement zwischen zwischen LeMaitre Vascular GmbH Otto-Volger-Straße 5a-5b 65843 Sulzbach Germany/Deutschland die „Gesellschaft” the „Company” Und And Peter Gebauer Lessingstr. 7 61440 Oberursel der „Geschäftsführer” - the „Managing Director” - wird folgende Vereinbarung geschlossen the following Agreement is made: 1. Beendigung des Anstellun |
|
| August 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2017 |
Transition and Employment Agreement dated June 7, 2017 between Peter R. Gebauer and the Registrant EX-10.2 EXHIBIT 10.2 TRANSITION AND EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of June 7, 2017 by and between LeMaitre Vascular, Inc., a Delaware corporation with an address at 63 Second Avenue, Burlington, MA, 01803 USA (“LMAT”), and Peter R. Gebauer, an individual with a residence at Lessingstraße 7, 61440 Oberursel, Germany (“Gebauer”). WHEREAS, as of the date hereof, Geb |
|
| July 27, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2017 LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33092 Delaware 04-2825458 (State or other jurisdiction (IR |
|
| July 27, 2017 |
LeMaitre Q2 2017 Record Sales $25.8 mm (+15%), Record EPS $0.23 (+69%) EX-99.1 Exhibit 99.1 LeMaitre Q2 2017 Record Sales $25.8 mm (+15%), Record EPS $0.23 (+69%) BURLINGTON, MA, July 27, 2017 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2017 results, provided increased guidance, announced a $0.055/share dividend and authorized a $7.5mm share repurchase program. Q2 2017 Results ? Record sales of $25 |
|
| July 7, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2017 LeMaitre Vascular, Inc. |
|
| June 9, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2017 LeMaitre Vascular, Inc. |
|
| May 31, 2017 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT LeMaitre Vascular, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 001-33092 04-2825458 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 63 Second Avenue, Burlington, MA 01803 (Address of Princi |
|
| May 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
